Compliance issues beset hypertension market
24 November 2011 | Dr Peter Charlish Scrip Clinical Research
Dr Reddy's polypill beats strong after FDA panel view AbbVie must undercut Gilead in hep C following EU approval FDA reviewers advise limited use for Daiichi Sankyo's edoxaban INTERVIEW: Oraya doesn't see threat from new AMD drugs
Other Features & Analysis
PCSK9 panels: Nissen's take How to help patients make treatments more effective When public policies collide: the battle to enforce second medical use patents for drugs in Europe Are there any early-phase opportunities left in hepatitis C?